Anti-CD19 FasT CAR-T Cell Therapy for B Cell NHL
Anti-CD19 FasT CAR-T Cell Therapy for Patients With B Cell NHL: a Multi-center, Uncontrolled Trial.
Sponsor: 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
This EARLY_PHASE1 trial investigates Lymphoma, Non-Hodgkin and is currently ongoing. 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China leads this study, which shows 8 recorded versions since 2020 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Unknown EARLY_PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Unknown EARLY_PHASE1
-
Aug 2024 — Sep 2024 [monthly]
Unknown EARLY_PHASE1
-
Jul 2024 — Aug 2024 [monthly]
Unknown EARLY_PHASE1
Status: Unknown Status → Unknown
-
Dec 2023 — Jul 2024 [monthly]
Unknown Status EARLY_PHASE1
Status: Not Yet Recruiting → Unknown Status
▶ Show 3 earlier versions
-
Oct 2021 — Dec 2023 [monthly]
Not Yet Recruiting EARLY_PHASE1
-
Jan 2021 — Oct 2021 [monthly]
Not Yet Recruiting EARLY_PHASE1
-
Dec 2020 — Jan 2021 [monthly]
Not Yet Recruiting EARLY_PHASE1
First recorded
Nov 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
- Chongqing University Cancer Hospital
- Gracell Biotechnologies (Shanghai) Co., Ltd.
- The Affiliated Hospital Of Guizhou Medical University
- The Second Affiliated Hospital of Chongqing Medical University
- The Second Affiliated Hospital of Kunming Medical University
- Xinqiao Hospital of Chongqing
For direct contact, visit the study record on ClinicalTrials.gov .